News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Week in Review: Deals and Drugs in China Biopharma


3/3/2008 2:26:59 PM

March 1, 2008 -- China Sky One Medical put some of its newly raised cash to work, paying $8.3 million to buy Heilongjiang Tianlong Pharma; Lotus Pharma garnered $5 million in a private placement; the time limit has expired on a $146 million agreement to sell the OTC drug business of Topsun Technology to Bayer AG; Novartis revealed that Novartis-China generated 2.5 billion RMB ($342 million) of revenue during 2007; China Pharma Holdings highlighted the revenues of its generic cold medication; BMP Sunstone announced that Propess® was recommended as a first-line treatment for labor induction; Provectus Pharma was granted patents in China and Europe for a cancer imaging agent; and the Executive Editor of ChinaBio® Today, Greg Scott, took questions from CCTV and Windover Information on the state of biopharma in China. More details...

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES